Skip to main content
. 2023 Apr 6;108(10):2794–2798. doi: 10.3324/haematol.2022.282639

Figure 2.

Figure 2.

Survival by propensity score match analysis between measurable residual disease (MRD)-unguided and MRD-guided groups, and subgroup analysis of only MRD-negative patients. (A) Event-free survival (EFS) after 36 months was 47% for the MRD-unguided group and 54% for the MRD-guided group (Hazard Ratio [HR]: 0.87; 95% confidence interval [CI]: 0.60-1.26; P=0.47). (B) Overall survival (OS) after 60 months was 56% in the MRD-unguided group and 61% in the MRD-guided group (HR: 0.80; 95% CI: 0.52-1.24; P=0.32). (C) EFS for MRD-negative patients after 36 months was 48% in the unguided group compared to 56% in the MRD-guided group (HR: 0.86; 95% CI: 0.56-1.33; P=0.50). (D) OS after 60 months was 60% in the unguided group, compared to 64% in the MRD-guided group (HR: 0.84; 95% CI: 0.50-1.40; P=0.50).